Gilead Sciences, Inc.





Market Closed - Nasdaq 03:59:59 2023-12-11 pm EST Intraday chart for Gilead Sciences, Inc. 5-day change 1st Jan Change
80.08 USD +1.34% +2.22% -6.72%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transgene: new CFO, share price rises CF
IDEAYA Biosciences Collaborates With Gilead Sciences to Evaluate Combination of Trodelvy, IDE397 for Bladder Cancer MT
Ideaya Biosciences, Inc. Announces Clinical Study Collaboration with Gilead Sciences, Inc. to Evaluate Trodelvy and Ide397 Combination in Mtap-Deletion Bladder Cancer CI
Wall Street: ideal end to the session, perfect November CF
Amazon: 'Black Friday' and 're:Invent' support the stock CF
Transcript : Gilead Sciences, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 09:00 AM CI
Novartis' Kymriah, Other CAR-T Cancer Therapies Under US Investigation Over Alleged Safety Issues MT
US FDA investigating safety risk of CAR-T cancer therapies RE
Health Care Down as FDA Probes Immunotherapy Treatments -- Health Care Roundup DJ
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells DJ
Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs DJ
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies MT
Transcript : Gilead Sciences, Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 01:20 PM CI
US FDA investigating safety risk of CAR-T therapies RE
HOOKIPA Pharma's HIV Vaccine Candidate HB-500 Receives FDA Clearance for Investigational New-Drug Application MT
China Excludes Fosun Kite's Yescarta from Medical Insurance Program MT
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
Sector Update: Health Care MT
Arcellx Shares Rise Premarket on Expanded Gilead Collaboration DJ
Arcellx Expands Partnership With Gilead Unit Kite MT
Gilead Invests Further in Arcellx, Extends Collaboration DJ
Transcript : Gilead Sciences, Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-15-2023 09:00 AM CI
Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc. CI
RBC Trims Price Target on Gilead Sciences to $77 From $78, Keeps Sector Perform Rating MT
UBS Adjusts Price Target on Gilead Sciences to $81 From $85, Maintains Neutral Rating MT
Chart Gilead Sciences, Inc.
More charts
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi.
-6.72% 98 462 M $
+59.64% 538 B $
+42.69% 430 B $
-12.22% 372 B $
-6.42% 264 B $
-5.93% 263 B $
-12.46% 232 B $
+2.38% 198 B $
-44.11% 163 B $
+3.62% 144 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Gilead Sciences, Inc. - Nasdaq
  4. News Gilead Sciences, Inc.
  5. Mizuho Securities Adjusts Gilead Sciences Price Target to $101 From $88, Maintains Buy Rating
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration